Current Assets
Income taxes receivable
Merck & Co. Income taxes receivable increased by 46.2% to $5.7B in Q4 2025 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ4 2025Feb 24, 2026
How to read this metric
An increase may suggest overpayment or tax credits, while a decrease indicates the collection of refunds or application of credits against current liabilities.
Detailed definition
This represents the amount of income tax overpayments or refundable credits owed to the company by government taxing aut...
Peer comparison
Common across large-cap pharmaceutical firms, often fluctuating based on the timing of tax filings and audit settlements.
Metric ID:
income_taxes_receivableHistorical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $3.9B | $5.7B |
| QoQ Change | — | +46.2% |
| YoY Change | — | +46.2% |
Range$3.9B – $5.7B
Avg YoY Growth+46.2%
Median YoY Growth+46.2%
Income taxes receivable at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s income taxes receivable?
- Merck & Co. (MRK) reported income taxes receivable of $5.7B in Q4 2025.
- What does income taxes receivable mean?
- The amount of money the government owes the company due to tax overpayments or credits.